Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non-Current Assets (2016 - 2025)

Catalyst Pharmaceuticals' Non-Current Assets history spans 16 years, with the latest figure at $209.9 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 7.84% year-over-year to $209.9 million; the TTM value through Dec 2025 reached $845.4 million, down 9.56%, while the annual FY2025 figure was $209.9 million, 7.84% down from the prior year.
  • Non-Current Assets reached $209.9 million in Q4 2025 per CPRX's latest filing, up from $199.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $250.8 million in Q4 2023 to a low of $24.8 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $147.6 million, with a median of $205.6 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: soared 13129.86% in 2021, then dropped 27.75% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $27.7 million in 2021, then soared by 98.05% to $54.8 million in 2022, then soared by 357.44% to $250.8 million in 2023, then fell by 9.16% to $227.8 million in 2024, then decreased by 7.84% to $209.9 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Non-Current Assets are $209.9 million (Q4 2025), $199.1 million (Q3 2025), and $213.2 million (Q2 2025).